Altimmune (ALT) Tax Provisions (2012 - 2025)

Altimmune (ALT) posted quarterly Tax Provisions of -$18.0 million for Q4 2025, down 2538.03% quarter-over-quarter from -$681000.0 in Q1 2025.

Analysis

Altimmune (ALT) Tax Provisions (2012 - 2025) Analysis & Trends

Altimmune (ALT) has reported Tax Provisions for 11 consecutive years, with -$18.0 million the latest figure, recorded in Q4 2025.

In Q4 2025, Tax Provisions changed N/A year-over-year to -$18.0 million; the TTM figure through Dec 2025 stood at -$18.6 million (changed N/A YoY), while the FY2025 annual figure was -$18.6 million, up 6.59% from the prior year.
Tax Provisions eased to -$18.0 million in Q4 2025 per ALT's latest filing, from -$681000.0 in the prior quarter.
Across five years, Tax Provisions topped out at $144000.0 in Q4 2022 and bottomed at -$18.0 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	139.62 Bn	131.77 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	85.73 Bn	77.73 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	63.53 Bn	58.35 Bn	1.37 Bn	-59.00 Mn
4	Moderna	58.23 Bn	53.09 Bn	52.00 Mn	15.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-	-
6	BeOne Medicines	40.03 Bn	34.93 Bn	1.53 Bn	75.45 Mn
7	Alnylam Pharmaceuticals	35.50 Bn	32.19 Bn	992.69 Mn	13.31 Mn
8	Royalty Pharma	28.52 Bn	27.68 Bn	-	-
9	Insmed	27.46 Bn	26.30 Bn	358.27 Mn	1.90 Mn
10	Altimmune	608.26 Mn	608.26 Mn	-	-

Historic Data

Download Data